Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) traded down 2.1% during trading on Friday . The company traded as low as C$1.85 and last traded at C$1.89. 80,575 shares traded hands during mid-day trading, a decline of 40% from the average session volume of 135,165 shares. The stock had previously closed at C$1.93.
Cardiol Therapeutics Stock Performance
The firm has a market cap of C$132.07 million, a price-to-earnings ratio of -4.30 and a beta of 0.70. The company has a quick ratio of 6.84, a current ratio of 2.39 and a debt-to-equity ratio of 1.07. The stock has a 50 day moving average of C$2.44 and a 200 day moving average of C$2.75.
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
See Also
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
